RxDoctor Payments Data

Nancy Branyas, MD

Cardiovascular Disease · Indianapolis, INNPI 1477527000

Payments from drug & device makers

$4,053in general payments, 2019–2025

Across 38 payments — averaging $106.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$542
  • Abbott$347
  • Amgen$125
  • Pfizer$107
  • Boehringer Ingelheim$38
  • plus $58 from 2 others

What the payments were for

  • Travel & lodging$1,53638%
  • Food & beverage$2,51762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)17$2,837
Boston Scientific8$542
Abbott3$347
Amgen1$125
Pfizer4$107
Boehringer Ingelheim2$38
Johnson & Johnson2$34
E.r. Squibb & Sons, L.L.C.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,053 in reported general payments places this provider in the 55th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$198,279
Medicare patients
1,353
Services billed
4,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban819$997,665
XareltoRivaroxaban175$184,253
EntrestoSacubitril/Valsartan70$121,293
MultaqDronedarone Hcl14$29,116
JardianceEmpagliflozin14$24,816
Dofetilide96$23,244
Metoprolol Succinate1,066$16,430
Propafenone Hcl186$11,780
Dabigatran EtexilateDabigatran Etexilate Mesylate24$9,013
Disopyramide Phosphate21$5,932
SotalolSotalol Hcl234$5,076
Nebivolol Hcl31$3,406
Potassium Chloride80$3,282
Mexiletine Hcl23$3,215
Midodrine Hcl12$3,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$107$997,665819 claims
Johnson & JohnsonXarelto$34$184,253175 claims
Boehringer IngelheimJardiance$38$24,81614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →